Top Story

Azacitidine, lenalidomide treatment appears safe for myelodysplastic syndrome, AML

January 26, 2015

A sequential treatment combination of lenalidomide and azacitidine appeared active in and safe for patients with high-risk myelodysplastic syndrome or acute myeloid leukemia, according to study results.

Azacitidine is a hypomethylating agent that is part of standard care for patients with myelodysplastic syndrome. However, responses to the drug have only been temporary, and after the initial treatment fails, the outcomes are poor, according to the study background.

FDA approvals

FDA grants orphan drug status to ovarian cancer treatment

January 26, 2015
The FDA granted orphan drug designation to liposomal encapsulated paclitaxel, or LEP-ETU, an ovarian cancer treatment in development by Insys Therapeutics Inc., the…
In the Journals

Majority of PCPs assigned high value to medical imaging

January 26, 2015
The majority of primary care physicians considered access to medical imaging to be essential to patient care, indicating that it aided in establishing earlier and more…
In the Journals

'Lack of understanding' about disease common in women with breast cancer

January 26, 2015
Many women with breast cancer possessed a poor understanding of their tumors and disease characteristics, according to study results.These knowledge deficiencies were…
Debasish Tripathy CommentaryMeeting News CoveragePublication Exclusive

Immunotherapy trials shift breast cancer research closer to ‘Holy Grail’

HemOnc Today, January 25, 2015
Debu Tripathy, MD
Immunotherapy is an area that has been a Holy Grail, if you will, in the field of breast cancer.We have long wondered whether the immune system could be harnessed to…
More News Headlines »
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage Video
Genome editing demonstrated wide application for blood disorders

Genome editing demonstrated wide application for blood disorders

January 4, 2015
SAN FRANCISCO — Ralph Green, MD, PhD, FRCPath, medical director of the UC Davis Health System Medical…
More »
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »